FGF10 and bronchopulmonary dysplasia: Specifically, SHS is known to induce NFκB levels by regulating proteasomal degradation of its endogenous inhibitor, IκB [21], which is anticipated as the potential mechanism for NFκB induction in BPD, similar to its role in other diseases states such as COPD, cystic fibrosis (CF), etc. In BPD, NFκB is also known to inhibit expression of fibroblast growth factor (FGF-10) that is essential for branching and morphogenesis of the conducting airways of the lungs [22].